{"id":51855,"date":"2025-12-23T20:53:32","date_gmt":"2025-12-23T12:53:32","guid":{"rendered":"https:\/\/flcube.com\/?p=51855"},"modified":"2025-12-23T20:53:33","modified_gmt":"2025-12-23T12:53:33","slug":"gileads-seladelpar-wins-china-hainan-approval-for-pbc-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=51855","title":{"rendered":"Gilead\u2019s Seladelpar Wins China Hainan Approval for PBC Treatment"},"content":{"rendered":"\n

Gilead Sciences<\/strong> (NASDAQ: GILD<\/a>) announced that Seladelpar<\/strong> (marketed as Livdelzi<\/strong>), a potent and selective PPAR\u03b4 agonist<\/strong> for Primary Biliary Cholangitis (PBC)<\/strong>, has been approved for use in the Hainan Boao Lecheng International Medical Tourism Pilot Zone<\/strong>. The drug, acquired from CymaBay Therapeutics for $4.3\u202fbillion<\/strong> in February\u202f2024, is indicated for PBC patients with inadequate response to ursodeoxycholic acid (UDCA)<\/strong> or as monotherapy in UDCA\u2011intolerant patients.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Details<\/th><\/tr><\/thead>
Approval Date<\/strong><\/td>22\u202fDec\u202f2025<\/td><\/tr>
Location<\/strong><\/td>Hainan Boao Lecheng International Medical Tourism Pilot Zone, China<\/td><\/tr>
Product<\/strong><\/td>Seladelpar (Livdelzi)<\/td><\/tr>
Indication<\/strong><\/td>PBC in adults (combination with UDCA or monotherapy)<\/td><\/tr>
Mechanism<\/strong><\/td>PPAR\u03b4 agonist (first approved for PBC globally)<\/td><\/tr>
Innovation<\/strong><\/td>First PPAR\u03b4 therapy<\/strong> for rare liver disease<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Global Approval Timeline<\/h2>\n\n\n\n
Date<\/th>Region\/Agency<\/th>Milestone<\/th><\/tr><\/thead>
Aug\u202f2024<\/strong><\/td>U.S. FDA<\/td>Accelerated approval (brand name Livdelzi)<\/td><\/tr>
Jan\u202f2025<\/strong><\/td>UK MHRA<\/td>Marketing authorization<\/td><\/tr>
Feb\u202f2025<\/strong><\/td>European Commission<\/td>Conditional marketing authorization<\/td><\/tr>
Sep\u202f2025<\/strong><\/td>Beijing Tianzhu Rare Disease Drug Security Pilot Zone<\/td>Approved for entry<\/td><\/tr>
Dec\u202f2025<\/strong><\/td>Hainan Boao Lecheng Pilot Zone<\/td>Medical tourism approval<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Opportunity<\/h2>\n\n\n\n
Metric<\/th>Value<\/th>Context<\/th><\/tr><\/thead>
China PBC Prevalence<\/strong><\/td>~70,000\u2011100,000 patients (2025)<\/td>Rare autoimmune liver disease; high unmet need<\/td><\/tr>
China PBC Market<\/strong><\/td>\u00a51\u20111.5\u202fbillion<\/strong> (\u2248\u202fUS$140\u2011210\u202fM)<\/td>Dominated by UDCA; limited second\u2011line options<\/td><\/tr>
Seladelpar Peak Sales<\/strong><\/td>\u00a5300\u2011500\u202fmillion<\/strong> (\u2248\u202fUS$42\u201170\u202fM) by 2030<\/td>20\u201130% share of refractory PBC segment in China<\/td><\/tr>
Pricing Strategy<\/strong><\/td>Premium orphan drug pricing<\/td>Eligible for national reimbursement pilot programs<\/td><\/tr>
Acquisition Cost<\/strong><\/td>$4.3\u202fbillion<\/strong> (Gilead acquisition of CymaBay)<\/td>Validates asset value<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Implications<\/h2>\n\n\n\n